GURUFOCUS.COM » STOCK LIST » Latin America » Mexico » MEX » Biogen Inc (MEX:BIIB) » Definitions » Book Value per Share
Switch to:

Biogen (MEX:BIIB) Book Value per Share

: MXN1,717.43 (As of Mar. 2023)
View and export this data going back to 2013. Start your Free Trial

Biogen's book value per share for the quarter that ended in Mar. 2023 was MXN1,717.43.

During the past 12 months, Biogen's average Book Value Per Share Growth Rate was 25.00% per year. During the past 3 years, the average Book Value Per Share Growth Rate was 6.70% per year. During the past 5 years, the average Book Value Per Share Growth Rate was 7.30% per year. During the past 10 years, the average Book Value Per Share Growth Rate was 10.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Biogen was 105.70% per year. The lowest was -33.90% per year. And the median was 13.40% per year.

Biogen's current price is MXN5300.00. Its book value per share for the quarter that ended in Mar. 2023 was MXN1,717.43. Hence, today's PB Ratio of Biogen is 3.09.

During the past 13 years, the highest P/B Ratio of Biogen was 9.51. The lowest was 2.40. And the median was 4.89.


Biogen Book Value per Share Historical Data

The historical data trend for Biogen's Book Value per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Book Value per Share
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,298.34 1,444.62 1,396.66 1,520.58 1,813.93

Biogen Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Book Value per Share Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,517.60 1,644.98 1,784.58 1,813.93 1,717.43

Competitive Comparison

For the Drug Manufacturers - General subindustry, Biogen's Book Value per Share, along with its competitors' market caps and Book Value per Share data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Biogen Book Value per Share Distribution

For the Drug Manufacturers industry and Healthcare sector, Biogen's Book Value per Share distribution charts can be found below:

* The bar in red indicates where Biogen's Book Value per Share falls in comparison to its industry or sector. The grey bar indicates the Book Value per Share's extreme value range as defined by GuruFocus.



Biogen Book Value per Share Calculation

Biogen's Book Value Per Share for the fiscal year that ended in Dec. 2022 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(261,205-0)/144
=1,813.93

Biogen's Book Value Per Share for the quarter that ended in Mar. 2023 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(248,684-0)/145
=1,717.43

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.

Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.


Biogen  (MEX:BIIB) Book Value per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


Biogen Book Value per Share Related Terms

Thank you for viewing the detailed overview of Biogen's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Biogen (MEX:BIIB) Business Description

Biogen logo
Address
225 Binney Street, Cambridge, MA, USA, 02142
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021, followed by Leqembi in January 2023.

Biogen (MEX:BIIB) Headlines

Other Sources

12 Cheap Biotech Stocks To Buy

By Yahoo Finance 2023-01-25